Study of Arbaclofen for the Treatment of Social Withdrawal in Subjects With Autism Spectrum Disorders

Phase 2 Completed 150 enrolled Seaside Therapeutics, Inc.

RandomizedParallel-groupQuadruple-blindTreatment

Summary

To explore the efficacy, safety and tolerability of STX209 (arbaclofen) administered for the treatment of social withdrawal in subjects with autism spectrum disorders

Timeline

Start: 2011-05
Primary completion: 2012-08
Completion: 2012-09

Drugs

Evaluation	Drug	Modality	Dose	Route
Comparator	Arbaclofen	Small molecule	—	—

Study of Arbaclofen for the Treatment of Social Withdrawal in Subjects With Autism Spectrum Disorders

Summary

Timeline

Drugs

Indications